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Abstract:
Background:
Few Antiretroviral Therapy (ART) adherence trials investigate the reasons for intervention success or failure among HIV-positive
individuals.
Objectives:
To conduct qualitative research to explore the reasons for effectiveness of a 6-month mHealth (mobile health) trial that improved
adherence among ART patients in China. The intervention utilized Wireless Pill Containers (WPCs) to provide, real-time SMS
reminders, WPC-generated adherence reports, and report-informed counseling.
Methods:
We conducted in-depth interviews with 20 intervention-arm participants immediately following the trial. Sampling was purposeful to
ensure inclusion of participants with varied adherence histories. Questions covered adherence barriers and facilitators, and
intervention experiences. We analyzed data in nVivo using a thematic approach.
Results:
Of participants, 14 (70%) were male; 7 (35%) had used injectable drugs. Pre-intervention, 11 were optimal adherers and 9 were
suboptimal adherers, using a 95% threshold. In the final intervention month, all but 3 (85%) attained optimal adherence. Participants
identified a range of adherence barriers and facilitators, and described various mechanisms for intervention success. Optimal adherers
at baseline were motivated by positive adherence reports at monthly clinic visits-similar to receiving A+ grades. For suboptimal
* Address correspondence to this author at the Department of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue,
Boston, MA, USA, Tel: 617-414-1272; Fax: 617-414-1261; E-mail: lsabin@bu.edu
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adherers, reminders facilitated the establishment of adherence-promoting routines; data-guided counseling helped identify strategies
to overcome specific barriers.
Conclusion:
Different behavioral mechanisms appear to explain the success of an mHealth adherence intervention among patients with varying
adherence histories. Positive reinforcement was effective for optimal adherers, while struggling patients benefitted from reminders
and data-informed counseling. These findings are relevant for the design and scalability of mHealth interventions and warrant further
investigation.
Keywords: HIV treatment, ART adherence, Behavior change, Intervention trial, mHealth, China.

1. INTRODUCTION
Interventions to improve adherence to Antiretroviral Therapy (ART) medication regimens among people living with
HIV (PLHIV) are critical to achieve optimal outcomes. Poor adherence has serious consequences for patients, including
progression of HIV to AIDS, development of resistant strains of HIV, and death [1 - 7]. ‘Optimal adherence’ is often
interpreted as ≥95%, though other thresholds have been used [6, 8, 9], particularly in recent years as the potency of
current ART regimens suggests that lower adherence may be associated with viral suppression [10]. However,
sustaining high ART adherence is a challenge for many patients, with typical ART adherence ranging between 60-80%
[6, 11 - 14] and often declining over time [4, 15 - 18]. A number of interventions have been shown to improve ART
adherence [19 - 22]. Successful intervention approaches have included elements such as providing information to
patients, engaging them in discussions of cognition and adherence expectations, directly-observed therapy, nutrition
support, and drug-use treatment [22]. Mobile health (mHealth) interventions that use real-time monitoring strategies for
ART are a new approach that allow early identification of adherence lapses [23 - 25]. mHealth adherence interventions
have been shown to be effective in resource-limited settings, and among certain populations, such as people who inject
drugs (PWID), that often face specific challenges to achieving optimal adherence [25 - 27].
Relatively few studies have investigated the factors that determine success or failure of adherence interventions,
including those focused on ART. Candy et al., reviewed randomized trials using qualitative evidence on patients’ views
to help understand variation in the effectiveness of interventions to improve adherence to long-term drug therapy [28].
Their analysis identified common intervention components; the component most commonly associated with effective
interventions was ‘a focus on personal risk factors’. Ineffective interventions typically lacked this component. Other
components of successful interventions included ‘explaining the value of adherence’ or ‘provision of clear/appropriate
information on how to take medication’ [28]. While these findings are useful for informing the design of future
interventions, they do not fully explain the mechanisms behind the behavioral change(s) that result in improved
adherence or maintenance of optimal adherence at the individual level.
The China Adherence Through Technology Study (CATS) assessed efficacy of a novel mHealth adherence
intervention among HIV-infected individuals in China [29]. China is home to Asia’s second largest HIV epidemic, with
over 500,000 individuals living with HIV and indications that the annual rate of new infections is rising [30]. China’s
western and southern border regions have been hardest hit by HIV, largely due to easy access to and high use of heroin
in these areas [31]. Although China’s government has scaled up ART rapidly, with nearly 300,000 individuals initiated
on ART by 2015 [30], drug resistance is emerging as a major concern, a sign of suboptimal adherence [32, 33]. The
CATS trial was one of the first rigorous trials to assess an adherence intervention in China, and the first to report on the
efficacy of an intervention based on new real-time adherence monitoring technology [29]. One component of the trial
was to explore the views and experiences of trial participants regarding the intervention, particularly regarding use of
the Wireless Pill Containers (WPCs) that monitor adherence in real-time. In the present analysis, we examined the
results of this qualitative component. It encompassed In-Depth Interviews (IDIs) with a sample of CATS trial
participants to better understand the dynamics of intervention results. Specifically, we aimed to explore the mechanisms
of action behind success of the intervention, and whether they varied according to adherence at baseline.
2. MATERIALS AND METHODS
2.1. CATS Study Site and Intervention
The CATS study was conducted from December 2012 to April 2014 in Nanning, China, capital city of Guangxi
Province, and home to 7 million residents. Located on China’s southern border north of Vietnam, Guangxi has
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experienced a widespread heroin epidemic that has helped fuel the spread of HIV: recent estimates suggest that
80,000-100,000 individuals had been infected with HIV by 2011 [34]. We implemented CATS at the ART clinic
operated by the Guangxi Provincial Center for Disease Control and Prevention (CDC). In 2012, the clinic was staffed
with 4 physicians, 2 nurses, and 3 HIV counselors, and provided HIV treatment to over 1,000 patients. Most clinic
patients were on a twice-daily ART regimen consisting of nevirapine or efavirenz, plus lamivudine with stavudine or
lamivudine with zidovudine; patients initiating therapy typically started on a once-daily regimen of lopinavir/ritonavir
plus tenofovir or abacavir. Usual care involved monthly clinic visits for medication refills and frequent sessions with
adherence counselors at the request of a clinician or patient.
For the CATS trial, we enrolled 120 ART patients and provided each one with a WPC for one ART medication,
with the medication selected by the participant based on pill fit and patient preference for refilling frequency. The WPC
(Wisepill Technologies, Capetown, South Africa) recorded the date and time of each container opening and
communicated the data immediately to a central server. After three months of passive monitoring, participants were
stratified by “optimal” vs “suboptimal” adherence, based on a 95% threshold over the full 3 months. We then
randomized participants within each stratum to intervention or comparison arms for the 6-month trial. Intervention
participants received personalized text message reminders triggered when the WPC was not opened within 30 minutes
past prescribed dose time. They also received a WPC-generated report showing their adherence in the previous month at
each monthly clinic visit. Participants with suboptimal adherence in the prior month were required to participate in
counseling provided by trained adherence counselors using the reports; optimal adherers in the previous month had a
choice of engaging in report-informed counseling. The trial’s methods are described in detail elsewhere [29].
The CATS intervention resulted in improved mean on-time ART adherence and a greater likelihood of achieving
‘optimal adherence’, as defined by 95% on-time adherence [29]. The results showed an immediate and sustained
improvement in mean adherence among intervention participants who were suboptimal adherers (defined prior to
implementing the trial as <95% at baseline). Among optimal adherers at baseline, mean adherence remained above 95%
for the full intervention period (6 months) for intervention participants, whereas it declined among comparison
participants [29].
2.2. Qualitative Study Participants
Participants in the IDIs were all CATS trial subjects, and thus had met study criteria at the time of enrollment. They
were: receiving or initiating ART; aged 18 years or above; owned a mobile phone; and deemed at risk for poor
adherence by clinicians or themselves. Trial participants’ time on ART was an average of 2.5 years at randomization
[29]. For the post-intervention qualitative component, we purposefully identified 20 intervention arm subjects to
maximize a range of experiences (roughly 1/3 of intervention arm participants). This sample size was pre-determined
based on the team’s previous experience with the number of participants needed to reach saturation. First, we selected
all seven self-reported PWID. Next, we identified subjects randomly to yield equal numbers of optimal vs. suboptimal
adherers at baseline. Finally, we made adjustments to ensure inclusion of 3-4 female participants in each group (equal to
their overall proportion among trial subjects).
2.3. Data Collection
All 20 pre-selected subjects agreed to participate in an IDI at their sixth and final intervention visit to the study
clinic (Month 9 of the study). A trained interviewer, who had also served as the coordinator of the CATS trial,
conducted each IDI in Mandarin Chinese, using a semi-structured interview guide. The interview guide provided openended questions with follow-up probes on perceived adherence barriers and facilitators, and participants’ experiences
participating in, and views of, the CATS intervention. These encompassed features such as use of the WPC, reminders,
adherence reports, and data-informed counseling. Typical questions were: “Can you tell me about your experience with
the text message reminders?”, “Can you tell me about your feelings when you saw your adherence report?”, “Can you
tell me about your experiences with the counseling?”. The average length of the IDIs was 30 minutes (ranging from
20-50 minutes); all were audio-recorded. Demographic information was collected at enrollment into the CATS study.
The study was reviewed and approved by the institutional review boards at Boston University Medical Center in
Boston, Massachusetts, USA and the Guangxi Provincial CDC in Nanning, China. All participants provided written
informed consent.
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2.4. Data Analysis
The IDI audio-recordings were transcribed by one team member verbatim and translated into English by two dual
Chinese-English speakers. The resulting Chinese language and English language transcripts were then reviewed by a
third dual language-speaker for accuracy. Four Boston-based team members (two of whom were dual-language
speakers) read all the transcripts and analyzed the English-language versions in QSR NVivo 11. A preliminary analysis
by two members yielded major themes. Two additional team members started with these themes and used an iterative
approach to further explore them and sub-themes in depth. For instance, an initial theme was “positive views of the
counseling.” As further reading was pursued, we noted that participants commented on the ways in which counselors
helped them to surmount adherence barriers. We thus created a sub-theme, “help from counselors in overcoming
adherence obstacles.” In this way, a comprehensive theme codebook was developed to code each transcript
systematically. We compared responses by baseline adherence, adherence at month 9 (final intervention month),
gender, and PWID status. Responses were prioritized by their frequency; we also examined divergent views.
3. RESULTS
3.1. Baseline Characteristics of Study Participants
Of all participants, 14 (70%) were male (Table 1). Seven (35%) were PWID and seven also reported using noninjectable drugs (35%); six (30%) reported using both types of drugs. Three (17.65%) said they drank alcohol at least
3-4 times per week. The majority (15, 75%) were employed. Nine participants (45%) had been on ART for less than 6
months. At randomization, 11 (55%) were optimal adherers and nine (45%) were suboptimal adherers. In the final
intervention month, 10 (90.91%) of the 11 baseline optimal adherers and seven (78%) of the nine baseline suboptimal
adherers attained ≥95% adherence. The three who failed to achieve optimal adherence were: 1) a young male who was
suboptimal at baseline; 2) a middle-aged male who was optimal at baseline; and 3) a middle-aged female who was
suboptimal at baseline. None were among those with self-reported drug use. Individual-level information on key
parameters for each participant is provided in Table 2. Fig. (1) contains illustrative reports for optimal and suboptimal
adherers at two time points: Month 3 (final month before randomization) and Month 5 (second month of the
intervention).
Our analysis revealed several themes related to participants’ perceptions of adherence and their perceived barriers
and facilitators. Clear themes and sub-themes also emerged with respect to the intervention. These findings are
presented below, beginning with views toward adherence generally, and then covering barriers and facilitators, and
finally, views of the intervention. Direct statements are presented where appropriate. Where differences emerged by
baseline adherence, adherence in the last intervention month, gender, and drug use, these are highlighted.
Table 1. Characteristics of participants at baseline.
Demographic Characteristics

Number (%/SD)

Age, years, n (%)
18-24

2 (10.0)

25-34
35-44
Male, n (%)

10 (50.0)
8 (40.0)
14 (70.0)

Highest education level achieved, n (%)
Primary school only

2 (10.0)

Middle/secondary school

12 (60.0)

Beyond secondary school

6 (30.0)

Married, n (%)

7 (35.0)

Employed, n (%)

15 (75.0)

Monthly income, yuan, mean (SD)

2678.5 (2197.7)

Health Characteristics
Optimal adherence ≥95%, n (%)

11 (55.0)

Time on ART, months, mean (SD)

23.8 (28.4)

Time on ART <6 months, n (%)

9 (45.0)

Twice/daily (vs. once/daily) regimen, n (%)

11 (55.0)

Used injectable street drug (ever), n (%)

7 (35.0)
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(Table 1) contd.....

Demographic Characteristics

Number (%/SD)

Used non-injectable drug (ever), n (%)

7 (35.0)

Used both injectable and non-injectable drug (ever), n (%)

6 (30.0)

Alcohol use 3-4 times per week or greater, n (%)
3 (17.7)
Note: Most characteristics were similar to those of the entire intervention-arm sample in the CATS trial, with the exception of injectable and noninjectable drug use, which was 11% and 13%, respectively [29]

3.2. Views Regarding Adherence
All participants said that being adherent was of personal importance. This stemmed from their understanding of the
clinical necessity of ART and that being adherent would keep the disease under control. Statements about adherence
were intermingled with a sense of confidence and optimism, even among suboptimal adherers. As one such participant
explained: “I am confident in taking my medicine continuously.” (Male, 28, baseline suboptimal)
Most participants stated that they felt personally responsible for their health, and that the rationale for adhering to
therapy was to ensure effective treatment and good health:
It’s [taking the medication] for myself. I want to live a better life and to be healthier. –Female, 29,
baseline suboptimal
Taking my medicine is the top priority and nothing could change our punctuality in taking medicine, no
matter how busy we are. - Male, 40, baseline optimal
Table 2. Key Characteristics of Individual Participants.
Participant
Number

Self-Reported
Age (at
time of Gender Injectable Drug use
IDI)
(yes/no)1

Self-Reported NonInjectable Drug use
(yes/no)2

Pre-Intervention Adherence
(Months 1-3)3

Adherence in Last
Intervention Month
(Month 9)3

1

32

M

Yes

Yes

optimal

optimal

2

22

M

No

No

suboptimal

suboptimal

3

20

M

No

No

optimal

optimal

4

40

M

Yes

Yes

optimal

optimal

5

35

M

Yes

No

suboptimal

optimal

6

38

F

Yes

Yes

optimal

optimal

7

28

M

No

Yes

suboptimal

optimal

8

26

M

No

No

optimal

optimal

9

34

M

Yes

Yes

optimal

optimal

10

30

F

No

No

suboptimal

optimal

11

33

F

No

No

suboptimal

optimal

12

29

F

No

No

suboptimal

optimal

13

35

M

No

No

optimal

suboptimal

14

40

M

Yes

Yes

optimal

optimal

15

33

M

No

No

suboptimal

optimal

16

32

M

No

No

suboptimal

optimal

17

35

F

No

No

suboptimal

suboptimal

18

42

M

Yes

Yes

optimal

optimal

19

35

M

No

No

optimal

optimal

20

31

F

No

No

optimal

optimal

1

Yes denotes heroin use; 2of 7 who self-reported non-injectable drug use: 6 had smoked heroin, 2 had taken methadone, 2 had snorted or swallowed
ketamine, 1 had snorted or swalled amphetamines or methamphetamines, and 1 had smoked opium; 3optimal adherence refers to ≥ 95% adherence and
suboptimal adherence refers to <95% adherence as measured by a real-time wireless pill monitor.

3.3. Perceived Barriers and Facilitators
Several themes emerged related to perceived barriers and facilitators of adherence. The main barriers mentioned
were job-related issues, feared stigma related to HIV, and unplanned events. Facilitators encompassed having a daily
routine, using reminders, and social support. These are each discussed below.
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Fig. (1). Examples of Wireless Pill Container adherence reports. Graphs show the adherence history in the pre-intervention period
(Month 3, in graphs to the left) and in the second intervention month (Month 5, in graphs to the right) for two subjects. 2a (top):
Reports for a patient with suboptimal adherence; 2b (bottom): Reports for a patient with optimal adherence.

3.3.1. Barriers
Work-related barriers were noted by most (75%) participants. Most typically, they explained that they were busy at
work and would either forget to take their medication or would be unable to “get away” to take a dose. As one
participant, a truck driver, explained:
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The biggest challenge is that, when I’m driving on the highway, etc., there is no rest stop. For example, I
could take my medicine from 10 to 12, but I may have already been on the highway before 10 and still
haven’t reached the next service stop at 12. In that case, I’d miss the time for my medication. –Male, 33,
baseline suboptimal.
Certain types of employment, namely those that allowed for breaks, were viewed as more supportive of medicationtaking than others. For example:
What I did for a living before [hairdresser], I can’t just stop what I was doing and take my medicine
immediately…. It will also be a problem for waiters in restaurants. But for cashiers working in a
supermarket or internet-café, they may just excuse themselves by saying that they need to drink some
water. –Male, 28, baseline suboptimal
Divergent views emerged regarding which types of employment posed barriers. In contrast to the statement above, a
female participant who worked as a shelf-stocker noted that being a cashier could be challenging for timely dose-taking:
“Cashiers cannot pause [to take medication].” (Female, 33, baseline suboptimal)
Another barrier was fear of revealing HIV status, both within and beyond work settings. Many participants said they
wanted to hide their status from their boss or coworkers, making it imperative to find a private place to take their
medications. This could be challenging, as explained by two participants:
Once I was on a business trip and I was half an hour late taking my medicine. That’s because the bag
with my bottle in it was stored in the trunk of the car and my boss was driving. The car didn’t stop then,
and I was too shy to ask him to pull over. -Male, 35, baseline optimal
Sometimes I have meetings until very late and I couldn’t just walk away. It was a bit inconvenient in
those situations…. We have strict rules for meetings. We were not allowed to leave freely…. We were not
even allowed to take phone calls. -Male, 35, baseline optimal
Fear of inadvertent disclosure was also an issue for those whose social network (i.e., family, friends) remained
unaware of their status. Most participants’ families and/or partners knew their status, but some did not. This could lead
to dose-taking delays. As two participants with suboptimal adherence explained:
I was having a walk with another person, and there was no water [to take the medication with] along the
way. I couldn’t just leave…. There was no bathroom either. Nothing. -Female, 30, baseline suboptimal
It feels really troublesome. I’m worried that other people will see me opening the pill bottle and wonder
what medicine I have in there. They will feel strange…. I was worried about my friends. -Female, 29,
baseline suboptimal
Another major theme was the importance of having a routine, and conversely, the way that unexpected events jolted
routines, requiring negotiation and often resulting in late or missed doses. In these cases, participants could not plan
ahead to ensure timely dose-taking:
There are some unexpected situations. Our lives are not very stable, nor are our jobs. I’m basically a
freelancer, so sometimes things just happen out of the blue. Everything is possible. -Male, 40, baseline
optimal
In addition, one participant, a PWID, highlighted the effect of drinking alcohol. In his words: “Sometimes I forgot. I
drank too much and got drunk.” (Male, 35, baseline suboptimal). Another PWID acknowledged the negative
consequences of illegal drug use, noting that he had been compelled to take a dose late when hiding from the police.
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3.3.2. Facilitators
Regarding adherence facilitators, most participants stressed the importance of maintaining or establishing a routine
as the key to sustaining optimal adherence. Having a routine meant incorporating dose-taking into daily activities on a
regular basis:
It feels like a part of my life and when it’s time, I’d take them. I have been on medication for so long, I
won’t forget at all. When it’s time, I definitely will get them out and take them, just like having meals
every day. -Male, 42, baseline optimal.
This theme was consistent among all groups of participants, with failure to establish and maintain a routine
emerging as a reason for lack of improved adherence during the intervention. In the words of one suboptimal adherer at
baseline as he reflected on his persistently low adherence: “The main problem was a lack of routine.” (Male, 22,
baseline suboptimal)
Another facilitator was the presence of a reminder system. Many participants reported relying on an alarm-most
frequently a phone-based reminder-to prompt them to take a dose. As one participant explained:
Usually when my alarm goes off, I’d grab the bottle out of my bag with one hand and snooze the alarm
with my other hand. Therefore, I don’t think I could miss my medicine. -Male, 35, baseline optimal
A third facilitator was having social support. Participants stressed that it helped them to be with people who knew
their HIV status, and described the role that their families and friends played in reminding them to take their doses.
Several participants referenced their “patient friends”, referring to HIV-positive friends. They alluded to social
activities, as well as conversations about the WPC, with these friends:
People in my circle basically know about it. I have a friend now. He checks my text messages …. and
then he’d tell me to be on time next time. -Female, 35, baseline suboptimal
My family knows about it, [and] so do my patient friends. Except for my patient friends, I was worried
about being seen [with the WPC] by other people. -Male, 40, baseline optimal
All participants also reported a good relationship with the clinicians at the study clinic; most described feeling
supported by the doctors and counselors, including all of the PWID. Their descriptions revealed their high regard for the
counselors, whom they claimed conveyed “mutual understanding.” One female PWID explained:
Sometimes when we have something bothering us in our life, they would also comfort me. It feels like
having a friend at the same level. I’m not that suppressed like when I’m outside. -Female, 38, baseline
optimal.
Only one participant suggested that encounters with a clinician might be unsupportive. This participant, a male
whose adherence was suboptimal at baseline and failed to improve over the intervention, said that if he did not take his
medications as directed, “I would be criticized.” (Male, 22, baseline suboptimal)
Several specifically mentioned that the counselors played a supportive role regarding ART. This is an illustrative
statement:
I think it also serves as mental assistance [talking to clinicians or counselors]. It is possible that nobody
around us knows that we are taking this medicine…. Only when I’m here for the consultation, would I
tell the consultants my difficulties. -Male, 20, baseline optimal
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3.4. Effect of the Intervention
Five major themes emerged that were related directly to the effect of the intervention, including: salutary
“supervisory effect;” the motivating influence of objective feedback; the role of the reports in promoting accountability;
text messages as simple reminders or to establish routines; and the usefulness of counseling in overcoming barriers.
3.4.1. Salutary “Supervisory Effect”
Participants described a beneficial supervisory effect of the intervention, particularly WPC use. The specific words
they used included “self-imposed pressure,” “invisible pressure,” “a supervisor,” and “like a teacher overseeing.”
Participants were aware that the WPC sent wireless signals that recorded their adherence, and they liked the sense of
‘being watched.’ In this sense, the WPC also served as a cue to action, urging participants to take their medication.
Participants also described how the WPC helped condition them to establish a habit of timely dose-taking:
I think the bottle is equivalent to an invisible pressure to remind myself of taking medicine on time. It
seems I won’t forget when I see it. Now, I basically begin to think that it’s half an hour for me to take my
medicine at 9:30, and whatever I’m doing, I will have this in mind. -Male, 20, baseline optimal
Most of the time, participants revealed positive feelings about this “supervisory effect,” claiming that it was a
helpful type of pressure that supported high adherence. Only one male participant, suboptimal at baseline, expressed an
opposing view, saying that “the self-imposed pressure was ever growing,” causing him to worry frequently. (Male, 22,
baseline suboptimal)
3.4.2. Objective Feedback via Reports led to Greater Awareness and Motivation
All participants liked the adherence reports, claiming that they were a helpful reference for maintaining or
improving adherence. Participants said the reports provided a visual depiction of their punctuality that was easy to read
and to use for identifying late or missed doses. The reports heightened their awareness of recent medication-taking
behavior, including changes in such behavior:
Now I see 96.6 [percent] for this month and it used to be over 98. I would certainly be aware of the
wrong time taking my medicine in this month. I can’t make the same mistake the next month. It just
reminds me to have this awareness. -Female, 38, baseline optimal
I was not punctual at the beginning…. It’s better when I have that …[the adherence report] as reference.
You can know about your situation through this…. I can read it and if I was not punctual, I’d pay more
attention. -Male, 28, baseline suboptimal
Participants described feeling happy and satisfied when they received a report showing optimal adherence in the
previous month. Participants who were optimally adherent at baseline stressed the way that the report was encouraging
and reinforced positive adherence behaviors. As one male participant explained: “When I see the straight line…. I’d feel
satisfied for the past month. It makes me happy and I think it’s encouraging.” (Male 26, baseline optimal) Participants
who had late or missed doses reported feeling badly. However, this was generally viewed as motivation to improve the
report for the next month. One participant explained:
It is [helpful]. The time before last time, I missed once and I felt pretty bad about it. Once I was late and
only took it after the set time. I quite care about this 100% [goal]. -Male, 33, baseline suboptimal
3.4.3. Reports Promoted Accountability
While personal motivation was important, many participants revealed a desire to please the clinicians, to “follow the
doctor’s orders” (Male 42, baseline optimal). One participant explained his motivation for being adherent: “Half for my
own health, and half … to do what the doctors want me to do.” (Male, 40, baseline optimal)
Participants viewed their relationship with the doctor as somewhat contractual and being adherent as a “promise” to
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the doctors. They saw themselves as trustworthy and did not want to break this promise. One participant explained:
I care about other people’s opinions when I do something and I wish to do it well…. I take my promise
seriously and I’m a man of my word. When I break my promise, the first thing I do is to blame myself,
and next, I’d be concerned about whether other people are angry and think that I’m not trustworthy. Male, 33, baseline suboptimal
To this end, the report provided an objective record of adherence that promoted a sense of accountability to doctors,
counselors, and to the patients themselves.
The pillbox can prove that I have been taking my doses on time, and the clinicians would know that I am
adherent…. to let them know I have been taking my doses on time, and I am following their instruction. Male, 32, baseline optimal
For example, [in the past] it would be natural to tell them that I didn’t miss my medication when they
ask. [Now] had I really missed, even if I could lie about it, I’d still feel hesitant and I’d feel perturbed. Male, 26, baseline optimal
As for the [adherence report], he [the counselor] said to me, “look, you didn’t take your medicine on
time, it looks like a wave”. I said, “really? I thought I was on time”…. Did you notice that I have more
straight lines now? -Male, 28, baseline suboptimal
3.4.4. Text Messages as Simple Reminders or to Establish Routines
Overall, participants viewed the text messages as a useful reminder if a dose had been forgotten. Occasionally
signals were not transmitted immediately upon opening of the WPCs, so some participants reported receiving a
reminder after having taken their medication, though this was not viewed as burdensome. A typical statement about the
reminders was: “...definitely useful. For example, it would remind you if you forget to take your medicine. The feeling is
that I’d think about whether I had forgotten to take my medicine. I’d recall whether I had forgotten and then take it if I
had.” (Male, 35, baseline suboptimal)
Views of the text messages differed by adherence at baseline. Most optimal adherers said that they would have been
adherent without the reminders. However, they also noted that in the case of an unplanned event, unusual business, or
when a dose was forgotten, the text messages were helpful:
I think they [reminders] are useful as I can double check whether I have had my medicine. I can take it
then, if I haven’t. -Male, 35, baseline optimal
I have my alarm set at 9:45 and 9:55 separately. Sometimes I was busy doing homework or other things
when the alarm went off. I wanted to wait to take my medicine right on time, so I just kept on doing what
I was doing until it was 10:30, when the message came in. Then I’d realize that I forgot to take my
medicine, and I’d take it immediately. -Male, 20, baseline optimal
Some high adherers noted that the text messages were a general reminder of the need for consistent dose-taking:
This pill bottle is a reminder. You have to remember to take your medicine on time; otherwise you’ll get
a text message. That’s how I feel. I think it helps you to form the idea that you have to take your medicine
when it’s time. -Female, 38, baseline optimal
Among suboptimal adherers at baseline, most participants viewed the text messages as helpful both in alerting them
to missed doses and in helping them to establish a routine to support on-time adherence behaviors. Only a few said they
thought the reminders were not critical because they would still use an alarm. A typical statement was:
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I remember that this thing would remind me later; I would just hurry and take it [medication].
Otherwise, I’d get a text message reminder later. Because of this mindset, I must hurry to open the bottle
and take my medicine within half an hour. That’s the type of mindset that pushes me to hurry, to be
comparatively more punctual. -Female, 29, baseline suboptimal
One participant said that she had used an alarm previously, but had come to rely on the text messages instead
because they were more discreet.
I used to set an alarm, but I don’t set it very often now.... Don’t you think that people might wonder why
you always run away when it was time? Now I set it on vibration. …I already remember the time now
after a while…. For now, I’ll just rely on this text message. -Female, 33, baseline suboptimal
3.4.5. Usefulness of Counseling in Overcoming Barriers
Among participants who engaged in data-informed counseling, which was required only when the report showed
<95% adherence in the prior month, all were positive about the counseling. This is an illustrative statement about the
counseling during the intervention, by the same participant who noted that counselors could sometimes be critical:
I [learned] more about adherence. I could forget if I was told just once, but through repeated
counseling, I would take the information more seriously. The counselors gave me different examples, like
a patient who could always take his ARVs [antiretroviral medications] on time or a patient who was not
adherent, and the consequences. -Male, 22, baseline suboptimal
Over the course of the intervention, many participants identified a personal barrier to adherence and then devised a
strategy to overcome it. Sometimes these were simple strategies like finding excuses to leave to go take their medication
when out with friends or at work. Sometimes it was a matter of planning ahead how to take a pill more discreetly or
punctually.
At the beginning, I used a small bag and I couldn’t open my pill bottle in the open public. My bag then
was narrow and I could only open it vertically…. Now I have a bigger bag, I can open it horizontally. Male, 28, baseline suboptimal
I think it takes some planning ahead…. I need to have the pill bottle with me all the time. You have to
carry your bottle when you’re not sure whether you can get back in time. - Male, 35, baseline optimal
I’d take it in bed when I’m in my dorm because there are lots of things in my bed, which could serve as a
screen. Plus my dorm mates wouldn’t notice when they are playing games. When I’m out, using the
bathroom is the most frequently used excuse, as this is normal. -Male, 20, baseline optimal
Many participants enacted a strategy suggested to them by a counselor. As two participants explained, including one
who remained suboptimal at the end of the intervention:
For instance, [they suggested that I] change my habit and set the alarm clock ahead of my dose time.
Now, I don’t go to bed even if I am very tired and sleepy. I would wait until I take my doses. -Male, 22,
baseline suboptimal
The pill bottle makes some noises when it’s getting empty. They told me to put some cotton wool in it. Male, 20, baseline optimal Occasionally, counselors advised not using the WPC in order to facilitate
dose-taking. As the participant quoted above explained: “[Counselors also said that] if I were truly
afraid of being seen by other people, I could take the meds out in advance and put them somewhere easy
to reach, which simplifies the process.” (Male, 20, baseline optimal)
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While most participants reported success in overcoming personal barriers to achieve optimal adherence, one
participant who failed to achieve optimal adherence explained his inability to change certain habits:
I have changed my habit of going to sleep too early. I am limiting my computer game playing as well. I
would try to set one more alarm [on my cellphone] 10 minutes after the first alarm, but I feel that would
also be a problem. It is a bit annoying. When I play computer games, I cannot stop. -Male, 22, baseline
suboptimal
4. DISCUSSION
This qualitative study aimed at exploring the reasons that an mHealth ART adherence intervention trial in China
proved successful in helping HIV-positive participants who were suboptimal adherers to improve their adherence, and
in supporting maintenance of high adherence among those who began the trial with optimal adherence. Generally, we
found that perceptions of the value of adherence, as well as perceived facilitators and barriers played an important role
in adherence behaviors for participants. All participants showed a clear understanding of the importance of adherence
and motivation to achieve optimal adherence. That they understood that adherence was key to successful treatment may
reflect the fact that the study took place in a large city in China that had been providing ART services for some time,
with the result that patients had absorbed the messaging provided by clinicians and counselors regarding adherence.
Most also revealed strong internal motivation to achieve optimal adherence. Thus, lack of understanding or motivation
to adhere does not explain poor adherence among those participants who failed to maintain or achieve optimal
adherence by the end of the trial.
Participants described a number of issues they believed acted as barriers to adherence. These included: work issues,
fear of revealing HIV status, and unplanned events. Both employment-related barriers and stigma have been well
documented in the ART adherence literature, including in China [35 - 40]. Unplanned events-or changes in one’s
regular schedule-has also been a common ART adherence barrier in numerous settings [39, 40], along with the related
phenomenon-forgetfulness [39, 41]. One previous study has shown a link between a ‘chaotic life’ (self-reported) and
missed outpatient visits among HIV-positive individuals [42]. Missed outpatient visits are a likely indicator of poor
ART retention and thus may also be indicative of poor adherence since retention in care is required for adherence to a
medication regimen.
In our analysis of these qualitative data, five clear themes emerged that help clarify the reasons for the trial’s
positive effect on adherence. These encompassed: a beneficial “supervisory effect” of the WPC; the motivating effect of
receiving objective adherence feedback; a sense of accountability that was encouraged by adherence reports; the way
that triggered reminders served as simple reminders and/or helped establish routines; and the role of counseling in
overcoming barriers. Woven through these themes was a strong recognition of the importance of personal awareness
and accountability; these were consistent across adherence level at baseline, gender, and prior drug use. In part, this
recognition may be due to the fact that the majority of participants had been on ART for some time even before trial
enrollment-they were thus already experienced (and in some sense ‘successful’ since they were retained in care)
patients. Yet the intervention itself seemed to heighten such recognition in several important respects.
First, the “supervisory effect” of the WPC was viewed as beneficial. Participants liked being “watched,” claiming
that it naturally increased personal awareness of adherence. While our patients expressed this positive view, not all
patients will welcome a potential “Big Brother” feeling [43]. Second, the monthly adherence reports emerged as key to
enlightening participants about their monthly adherence patterns. This finding is less controversial; a recent review and
meta-analysis of adherence-enhancing interventions in 79 RCTs, including an assessment of “drug dosing histories”
(like the adherence reports used in CATS), found that giving patients feedback about their dosing behavior was the
largest factor influencing adherence [44]. Finally, the reports were instrumental in providing an objective record of the
prior month’s adherence that motivated participants to be accountable to themselves and to the doctors. The desire to
appear trustworthy and not disappoint one’s doctor may be a form of introjected motivation (actions taken to avoid guilt
or shame). Other studies have suggested that striving to save face may motivate behavior change in some populations
[45, 46].
While we found no clear differences in experiences or views by gender or PWID status, the differences between
those who were baseline optimal vs. baseline suboptimal adherers represent a key finding of this study. For participants
who already had high adherence, the intervention clearly provided support and motivation to maintain high adherence.
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In contrast to those who were suboptimal at baseline, optimal adherers had already established positive habits and a
routine of on-time adherence prior to intervention implementation. For this group, the reminders served mainly as a
reminder in rare cases of forgetfulness. However, the adherence report played an important role for this group. They
viewed the report as something akin to a report card. The receipt of a report that showed declining adherence, or even
worse, suboptimal adherence in the previous month, was viewed as a warning sign. This finding may help to explain
why the CATS intervention arm did not show the typical decline in adherence over time observed in other studies.
While declines in adherence have been commonly observed in prior studies, usually they are characterized as a “modest
decline” in adherence [15 - 18]. Although the threshold of 95% adherence is arbitrary, and a slight decline below 95%
may not have serious medical consequences, reports showing a decline to below 95% clearly prompted participants to
redouble their efforts to cross back over the 95% threshold. They desired a ‘good report,’ and wished to avoid the sense
of failure they associated with a ‘suboptimal’ report.
For participants who were baseline suboptimal adherers, the intervention seems to have worked through two key
mechanisms, regardless of gender or experience with drug use. First, the triggered text messages played an important
role in helping participants to establish habits that would lead to a pattern of on-time adherence. This is important
because the establishment or maintenance of a routine was fundamental to achieving optimal adherence over the course
of the intervention. The direct link between behavior (being late for a dose or headed toward missing a dose altogether)
and receiving a reminder may have helped provide an immediate stimulus for behavior change. Here, participants’
knowledge of the importance of adherence, and their motivation to be adherent, are critical, encouraging them to view
the triggered reminders as a welcome support, rather than as annoying messages unassociated with behavior, as
automatic reminders have been viewed in other studies [47 - 52].
Second, the WPC-generated adherence reports and data-informed counseling were critical in helping suboptimal
participants overcome whatever personal barriers they were experiencing. As our findings show, the data-informed
counseling in particular presented an opportunity to discuss barriers and to strategize about solutions. Here, the positive
relationship with clinicians that participants described is particularly relevant. Were they to fear criticism, or were
clinicians unprepared for a supportive conversation, the counseling might not have contributed to the positive effect
found in CATS. Interestingly, the evidence on the potential impact of data-informed counseling is growing, including
from some of our previous work in China [9, 44, 53]. However, this study is the first of which we are aware that
provides clear evidence from ART patients themselves about how data-informed counseling assisted them in
overcoming barriers. Further studies to unpack the details of what is shared in these types of counseling sessions may
provide guidance about how to best use data to inform counseling.
Notably, few participants failed to achieve optimal adherence over the course of the intervention-only three among
the qualitative study sample. Little emerged from the qualitative data to help shed light on why the intervention did not
succeed with these participants. Indeed, the themes and sub-themes that surfaced from the data were generally
consistent among all participants regardless of whether their adherence was optimal in Month 9. The most notable
exception was the view expressed by one participant, a young male whose adherence remained suboptimal throughout
the intervention, who felt that being watched led to an “ever growing” self-imposed pressure that made him anxious.
This particular participant also conveyed somewhat mixed experiences with counseling: he stated that he would be
‘criticized’ when he was not adherent, and yet also conveyed positive views of the data-informed counseling, giving
examples of how the counselors helped him cope with specific pill-taking challenges. It would thus appear to be the
case that while struggling participants liked the intervention, and most of its separate features, it did not always spur
optimal medication-taking behaviors.
These findings have several important implications for informing the design of mHealth interventions for HIV
adherence, as well as for the scalability of this type of intervention. Our results regarding the central role of personal
barriers are notable because it suggests that what participants had previously lacked were strategies and support to
overcome these barriers. They support those of Candy et al., who found that a focus on overcoming personal risk
factors was a common thread of successful interventions for adherence [28].
In addition, our findings suggest that for ART patients who are already high adherers, real-time monitoring
combined with reports may provide sufficient support. However, further counseling appears necessary to help
suboptimal adherers overcome challenges. Our findings also help to address concerns as to whether the use of triggered
text-message reminders could train patients to take their medications only in response to a reminder, which might leave
patients vulnerable in the event of device failures or loss of cellular connectivity. The CATS study found that the
proportion of doses taken before the 30-minute mark increased during the intervention period, mitigating this concern
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[29]. The qualitative component corroborates this finding, indicating that text message reminders served to help
participants establish a habit of on-time adherence such that they no longer relied on the messages as medication
reminders.
4.1. Limitations
We note several study limitations. First, the topics discussed in the IDIs-views of HIV and adherence, motivations,
values, accountability, and relationship with clinicians, are all highly culture-specific and findings related to these
factors will undoubtedly vary in different settings and populations. Second, we were limited by the fact that the majority
of our participants succeeded in attaining optimal adherence by month 9, restricting perceptions of adherence ‘failure’.
Similarly, we used a binary (yes/no) measure to determine baseline adherence (suboptimal versus optimal), as well as
intervention success, defined as ≥95% adherence in month 9. This may have limited our comparisons between
suboptimal and optimal adherers at baseline, as such dichotomous categories do not capture the full extent of variability
within these categories. In addition, although electronic drug monitors are considered the gold standard in adherence
measures, we could not determine the reliability of the WPCs we used in CATS. It is possible that participants opened
the WPC because they knew they were being monitored, but did not take their medication. However, we believe a more
significant limitation may be that participants would occasionally take pills out of the container in advance for later
dosing without the device recording that they took the dose. Several participants reported doing this when they could
anticipate situations during which it would be difficult to use the device. Unfortunately, the HIV viral load outcomes
from the trial are not helpful in understanding the effect of this activity, primarily because most participants were
suppressed at randomization [29]. Finally, participants may have provided biased information due to poor recall or out
of a desire to please the interviewer, a common challenge in qualitative research. In this case, we do not believe the
latter was an issue because the interviewer was also the study coordinator at the study clinic and was familiar with the
issues that participants faced with their medications, having given them their detailed adherence reports and discussed
challenges with them over the previous 6 months of the intervention.
CONCLUSION
This study provides valuable insight regarding the factors driving the success of an mHealth intervention to promote
HIV adherence. Our findings help to elucidate the role of the different components of the CATS intervention in
contributing to change in adherence behaviors resulting in improvement or maintenance of optimal adherence. Notably,
our findings show the differential effect of the intervention observed among participants who were baseline optimal
adherers compared with baseline suboptimal adherers. These findings warrant further investigation because of their
implications for the design and scalability of mHealth interventions. Interventions should give consideration to patients’
prior level of adherence, and should ensure that patients are adequately supported to overcome personal barriers to
adherence, if necessary.
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